These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

72 related articles for article (PubMed ID: 17497727)

  • 1. Influence of operating temperature and pressure on the polymorphic transition of salmeterol xinafoate in supercritical fluids.
    Tong HH; Shekunov BY; York P; Chow AH
    J Pharm Sci; 2008 Feb; 97(2):1025-9. PubMed ID: 17497727
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of polymorphism on the surface energetics of salmeterol xinafoate crystallized from supercritical fluids.
    Tong HH; Shekunov BY; York P; Chow AH
    Pharm Res; 2002 May; 19(5):640-8. PubMed ID: 12069167
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of two polymorphs of salmeterol xinafoate crystallized from supercritical fluids.
    Tong HH; Shekunov BY; York P; Chow AH
    Pharm Res; 2001 Jun; 18(6):852-8. PubMed ID: 11474791
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Surface characterization of salmeterol xinafoate powders by inverse gas chromatography at finite coverage.
    Tong HH; Shekunov BY; York P; Chow AH
    J Pharm Sci; 2005 Mar; 94(3):695-700. PubMed ID: 15668948
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thermal analysis of trace levels of polymorphic impurity in salmeterol xinafoate samples.
    Tong HH; Shekunov BY; York P; Chow AH
    Pharm Res; 2003 Sep; 20(9):1423-9. PubMed ID: 14567637
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of salmeterol xinafoate microparticle production by conventional and novel antisolvent crystallization.
    Murnane D; Marriott C; Martin GP
    Eur J Pharm Biopharm; 2008 May; 69(1):94-105. PubMed ID: 17981448
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of agglomeration in the dispersion of salmeterol xinafoate from mixtures for inhalation with differing drug to fine lactose ratios.
    Adi H; Larson I; Chiou H; Young P; Traini D; Stewart P
    J Pharm Sci; 2008 Aug; 97(8):3140-52. PubMed ID: 18023007
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Polymorphic control of inhalation microparticles prepared by crystallization.
    Murnane D; Marriott C; Martin GP
    Int J Pharm; 2008 Sep; 361(1-2):141-9. PubMed ID: 18582548
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of carrier size on the dispersion of salmeterol xinafoate from interactive mixtures.
    Islam N; Stewart P; Larson I; Hartley P
    J Pharm Sci; 2004 Apr; 93(4):1030-8. PubMed ID: 14999738
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vibrational spectroscopic characterisation of salmeterol xinafoate polymorphs and a preliminary investigation of their transformation using simultaneous in situ portable Raman spectroscopy and differential scanning calorimetry.
    Ali HR; Edwards HG; Hargreaves MD; Munshi T; Scowen IJ; Telford RJ
    Anal Chim Acta; 2008 Jul; 620(1-2):103-12. PubMed ID: 18558130
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adhesion and redistribution of salmeterol xinafoate particles in sugar-based mixtures for inhalation.
    Adi H; Larson I; Stewart PJ
    Int J Pharm; 2007 Jun; 337(1-2):229-38. PubMed ID: 17303354
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predicting the aerosol performance of dry powder inhalation formulations by interparticulate interaction analysis using inverse gas chromatography.
    Tong HH; Shekunov BY; York P; Chow AH
    J Pharm Sci; 2006 Jan; 95(1):228-33. PubMed ID: 16315225
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro studies on the behavior of salmeterol xinafoate and its interaction with calf thymus DNA by multi-spectroscopic techniques.
    Zhao T; Bi S; Wang Y; Wang T; Pang B; Gu T
    Spectrochim Acta A Mol Biomol Spectrosc; 2014 Nov; 132():198-204. PubMed ID: 24866086
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dry powder formulations for inhalation of fluticasone propionate and salmeterol xinafoate microcrystals.
    Murnane D; Martin GP; Marriott C
    J Pharm Sci; 2009 Feb; 98(2):503-15. PubMed ID: 18506819
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of storage relative humidity on the dispersion of salmeterol xinafoate powders for inhalation.
    Das S; Larson I; Young P; Stewart P
    J Pharm Sci; 2009 Mar; 98(3):1015-27. PubMed ID: 18661537
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Agglomerate properties and dispersibility changes of salmeterol xinafoate from powders for inhalation after storage at high relative humidity.
    Das S; Larson I; Young P; Stewart P
    Eur J Pharm Sci; 2009 Jun; 37(3-4):442-50. PubMed ID: 19491036
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination particles containing salmeterol xinafoate and fluticasone propionate: Formulation and aerodynamic assessment.
    Westmeier R; Steckel H
    J Pharm Sci; 2008 Jun; 97(6):2299-310. PubMed ID: 17879293
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Solubility prediction of salmeterol xinafoate in water--dioxane mixtures.
    Jouyban-Gharamaleki A; York P; Hanna M; Clark BJ
    Int J Pharm; 2001 Mar; 216(1-2):33-41. PubMed ID: 11274804
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of the polydispersity of the added fine lactose on the dispersion of salmeterol xinafoate from mixtures for inhalation.
    Handoko A; Ian L; Peter SJ
    Eur J Pharm Sci; 2009 Feb; 36(2-3):265-74. PubMed ID: 18996188
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Using gold nanoparticles as probe for detection of salmeterol xinafoate by resonance Rayleigh light scattering.
    Bi S; Wang T; Wang Y; Zhao T; Zhou H
    Spectrochim Acta A Mol Biomol Spectrosc; 2015 Jan; 135():1074-9. PubMed ID: 25173524
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.